Overview

Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2020-07-09

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well lenalidomide and eltrombopag olamine works in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Albert Einstein College of Medicine
Albert Einstein College of Medicine of Yeshiva University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Lenalidomide
Thalidomide